Suppr超能文献

甲状腺癌中的 p21 激活激酶。

p21-Activated Kinases in Thyroid Cancer.

机构信息

Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, and Cancer Biology Program, The Ohio State University College of Medicine and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio.

Department of Hematology and Medical Oncology, Emory University and Winship Cancer Institute, Atlanta, Georgia.

出版信息

Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa105.

Abstract

The family of p21-activated kinases (PAKs) are oncogenic proteins that regulate critical cellular functions. PAKs play central signaling roles in the integrin/CDC42/Rho, ERK/MAPK, PI3K/AKT, NF-κB, and Wnt/β-catenin pathways, functioning both as kinases and scaffolds to regulate cell motility, mitosis and proliferation, cytoskeletal rearrangement, and other cellular activities. PAKs have been implicated in both the development and progression of a wide range of cancers, including breast cancer, pancreatic melanoma, thyroid cancer, and others. Here we will discuss the current knowledge on the structure and biological functions of both group I and group II PAKs, as well as the roles that PAKs play in oncogenesis and progression, with a focus on thyroid cancer and emerging data regarding BRAF/PAK signaling.

摘要

p21 激活激酶(PAKs)家族是致癌蛋白,调节关键的细胞功能。PAKs 在整合素/CDC42/Rho、ERK/MAPK、PI3K/AKT、NF-κB 和 Wnt/β-catenin 通路中发挥核心信号作用,既是激酶又是支架,调节细胞迁移、有丝分裂和增殖、细胞骨架重排和其他细胞活动。PAKs 参与了广泛的癌症的发展和进展,包括乳腺癌、胰腺黑色素瘤、甲状腺癌等。在这里,我们将讨论关于 I 组和 II 组 PAKs 的结构和生物学功能的最新知识,以及 PAKs 在致癌和进展中的作用,重点关注甲状腺癌和关于 BRAF/PAK 信号的新兴数据。

相似文献

1
p21-Activated Kinases in Thyroid Cancer.
Endocrinology. 2020 Aug 1;161(8). doi: 10.1210/endocr/bqaa105.
2
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
3
P21 activated kinase signaling in cancer.
Semin Cancer Biol. 2019 Feb;54:40-49. doi: 10.1016/j.semcancer.2018.01.006. Epub 2018 Jan 9.
4
Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
J Clin Endocrinol Metab. 2013 Aug;98(8):E1314-22. doi: 10.1210/jc.2012-3937. Epub 2013 May 24.
5
Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.
Endocr Relat Cancer. 2010 Oct 29;17(4):989-99. doi: 10.1677/ERC-10-0168. Print 2010 Dec.
6
BRAF activates and physically interacts with PAK to regulate cell motility.
Endocr Relat Cancer. 2014;21(6):865-77. doi: 10.1530/ERC-14-0424. Epub 2014 Sep 16.
7
p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Leukemia. 2022 Feb;36(2):315-326. doi: 10.1038/s41375-021-01451-7. Epub 2021 Oct 25.
8
p21-activated kinases and gastrointestinal cancer.
Biochim Biophys Acta. 2013 Jan;1833(1):33-9. doi: 10.1016/j.bbamcr.2012.10.015. Epub 2012 Oct 22.
9
Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
World J Gastroenterol. 2016 Jan 21;22(3):1224-35. doi: 10.3748/wjg.v22.i3.1224.
10
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Nature. 2017 Oct 5;550(7674):133-136. doi: 10.1038/nature24040. Epub 2017 Sep 27.

引用本文的文献

1
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells.
Endocr Relat Cancer. 2025 May 29;32(6). doi: 10.1530/ERC-24-0124. Print 2025 Jun 1.
2
CDK5 targets p21 to regulate thyroid cancer cell proliferation and malignancy in patients.
Mol Med Rep. 2025 Jul;32(1). doi: 10.3892/mmr.2025.13547. Epub 2025 Apr 25.
4
Tasquinimod promotes the sensitivity of ovarian cancer cells to cisplatin by down-regulating the HDAC4/p21 pathway.
Korean J Physiol Pharmacol. 2025 Mar 1;29(2):191-204. doi: 10.4196/kjpp.24.132. Epub 2024 Nov 14.
6
Inhibition of NAMPT by PAK4 Inhibitors.
Int J Mol Sci. 2024 Sep 21;25(18):10138. doi: 10.3390/ijms251810138.
7
FRAX486, a PAK inhibitor, overcomes ABCB1-mediated multidrug resistance in breast cancer cells.
Braz J Med Biol Res. 2024 Jul 1;57:e13357. doi: 10.1590/1414-431X2024e13357. eCollection 2024.
10
Potential Resistance to Antineoplastic Aminated Fullerenes Mediated by M2-Like Monocyte-Derived Exosomes.
Front Oncol. 2022 Mar 31;12:779939. doi: 10.3389/fonc.2022.779939. eCollection 2022.

本文引用的文献

1
Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017.
J Clin Endocrinol Metab. 2020 Jun 1;105(6). doi: 10.1210/clinem/dgaa121.
2
Targeting effector pathways in RAC1-driven malignant melanoma.
Small GTPases. 2021 Jul;12(4):273-281. doi: 10.1080/21541248.2020.1728469. Epub 2020 Feb 17.
4
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
Cancer Res. 2019 Oct 1;79(19):5074-5087. doi: 10.1158/0008-5472.CAN-19-0244. Epub 2019 Aug 15.
5
RAC1 Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.
6
MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Endocr Relat Cancer. 2019 Aug;26(8):699-712. doi: 10.1530/ERC-19-0188.
9
P21 activated kinase signaling in cancer.
Semin Cancer Biol. 2019 Feb;54:40-49. doi: 10.1016/j.semcancer.2018.01.006. Epub 2018 Jan 9.
10
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Oncogene. 2018 Feb 15;37(7):944-952. doi: 10.1038/onc.2017.400. Epub 2017 Oct 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验